WAP
ESPR icon

Wealthcare Advisory Partners’s Esperion Therapeutics ESPR Stock Holding History

Wealthcare Advisory Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$9.84K – 1032
2025
Q2 		$9.84K Buy
+10,000
New +$10K ﹤0.01% 967

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Wealthcare Advisory Partners's ESPR Position: Q3 2025 in Review

Wealthcare Advisory Partners sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 10,000 shares — an estimated $9.84K sold.

Wealthcare Advisory Partners first reported a position in ESPR in Q2 2025 and held it in 1 quarter. The position peaked at $9.84K in Q2 2025. 189 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Wealthcare Advisory Partners reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 10,000 Esperion Therapeutics shares in Q3 2025, an estimated $9.84K.
  • Wealthcare Advisory Partners first reported a position in Esperion Therapeutics in Q2 2025 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Esperion Therapeutics position peaked at $9.84K in Q2 2025.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2025, filed 7 Nov 2025.